The analysis of our review supports the concept of the beneficence of SGLT-2 inhibitors in T2DM patients, as these drugs had shown a more remarkable improvement of glycemic index, weight control, blood pressure reduction, and, most of all, MACE, hospitalizations for heart failure, and cardiovascular mortalities. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.